DE60312309D1 - Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten - Google Patents

Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten

Info

Publication number
DE60312309D1
DE60312309D1 DE60312309T DE60312309T DE60312309D1 DE 60312309 D1 DE60312309 D1 DE 60312309D1 DE 60312309 T DE60312309 T DE 60312309T DE 60312309 T DE60312309 T DE 60312309T DE 60312309 D1 DE60312309 D1 DE 60312309D1
Authority
DE
Germany
Prior art keywords
botulinum toxin
treat heart
diseases
circular
circular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60312309T
Other languages
English (en)
Other versions
DE60312309T3 (de
DE60312309T2 (de
Inventor
Gregory F Brooks
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28453838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60312309(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60312309D1 publication Critical patent/DE60312309D1/de
Publication of DE60312309T2 publication Critical patent/DE60312309T2/de
Publication of DE60312309T3 publication Critical patent/DE60312309T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60312309T 2002-04-01 2003-03-24 Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten Expired - Lifetime DE60312309T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US114740 1980-01-24
US10/114,740 US6767544B2 (en) 2002-04-01 2002-04-01 Methods for treating cardiovascular diseases with botulinum toxin
PCT/US2003/009157 WO2003084567A1 (en) 2002-04-01 2003-03-24 Use of botulinum toxin for treating cardiovasular diseases

Publications (3)

Publication Number Publication Date
DE60312309D1 true DE60312309D1 (de) 2007-04-19
DE60312309T2 DE60312309T2 (de) 2007-11-08
DE60312309T3 DE60312309T3 (de) 2011-02-24

Family

ID=28453838

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312309T Expired - Lifetime DE60312309T3 (de) 2002-04-01 2003-03-24 Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten

Country Status (13)

Country Link
US (4) US6767544B2 (de)
EP (1) EP1490097B2 (de)
JP (3) JP2005521735A (de)
KR (1) KR20040105818A (de)
AT (1) ATE355852T1 (de)
AU (1) AU2003220511C1 (de)
BR (1) BR0308928A (de)
CA (1) CA2480505A1 (de)
DE (1) DE60312309T3 (de)
ES (1) ES2281636T5 (de)
HK (1) HK1070575A1 (de)
MX (1) MXPA04009410A (de)
WO (1) WO2003084567A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302875B1 (en) 1996-10-11 2001-10-16 Transvascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
WO2003059192A2 (en) 2001-12-21 2003-07-24 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
AU2003259246A1 (en) * 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8073538B2 (en) 2003-11-13 2011-12-06 Cardio Polymers, Inc. Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
JP5089388B2 (ja) 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド 分解可能なクロストリジウム毒素
US7906124B2 (en) * 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
GB2419817A (en) * 2004-10-29 2006-05-10 Ipsen Ltd Treatment of cardiac fibrillation disorders
CN101076290B (zh) 2004-12-09 2011-11-23 铸造品股份有限公司 主动脉瓣修复
US9833618B2 (en) * 2005-02-04 2017-12-05 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DE602006017237D1 (en) 2005-04-05 2010-11-11 Allergan Inc Clostridientoxinaktivitätstests
US9511210B2 (en) 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20070237802A1 (en) * 2006-04-11 2007-10-11 Medtronic Vascular, Inc. Inhibition of Calcification on an Endovascular Device
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
CN102014779B (zh) 2008-05-09 2014-10-22 赫莱拉公司 用于治疗支气管树的系统、组件和方法
WO2010101968A1 (en) 2009-03-06 2010-09-10 Allergan, Inc. Clostridial toxin to improve ejaculate
EP2482838A4 (de) * 2009-09-30 2013-04-10 Toxcure Inc Verwendung von botulinum-neurotoxin zur behandlung von substanzabhängigkeit
CN112089394A (zh) 2009-10-27 2020-12-18 努瓦拉公司 具有可冷却的能量发射组件的递送装置
WO2011060200A1 (en) 2009-11-11 2011-05-19 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
EP2563459A1 (de) 2010-04-30 2013-03-06 Boston Scientific Scimed, Inc. Freisetzungsvorrichtung für ein therapeutikum zur freisetzung eines neurotoxins
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
EP2694150A1 (de) 2011-04-08 2014-02-12 Covidien LP Iontophorese-medikamentenabgabesystem sowie verfahren zur denervierung der renalen sympathischen nerven und iontophorese-medikamentenabgabe
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US20170246268A1 (en) * 2014-09-12 2017-08-31 Gary E.l BORODIC Longevity Enhancement Induced by Repetitive Injections of Botulinum Toxin (Centurion Effect)
PL3242884T3 (pl) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Kationowe neurotoksyny
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
CN109790204A (zh) 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
US11116561B2 (en) 2018-01-24 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Devices, agents, and associated methods for selective modulation of renal nerves
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092841A (en) * 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
AU4282793A (en) † 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
US6121296A (en) * 1992-11-04 2000-09-19 Albert Einstein College Of Medicine Of Yeshiva University Transition-state inhibitors for nucleoside hydrolase and transferase reactions
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5989280A (en) * 1993-10-22 1999-11-23 Scimed Lifesystems, Inc Stent delivery apparatus and method
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE69434610T2 (de) * 1993-12-28 2008-11-27 Allergan, Inc., Irvine Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3066079B2 (ja) * 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． 頭痛を低減する方法
US5626562A (en) 1994-11-28 1997-05-06 Devices For Vascular Intervention Drug delivery catheter
US6102904A (en) * 1995-07-10 2000-08-15 Interventional Technologies, Inc. Device for injecting fluid into a wall of a blood vessel
US6261318B1 (en) 1995-07-25 2001-07-17 Medstent Inc. Expandable stent
US5851786A (en) * 1995-09-27 1998-12-22 National Jewish Center For Immunology And Respiratory Medicine Product and process to regulate actin polymerization
CA2192520A1 (en) * 1996-03-05 1997-09-05 Ian M. Penn Expandable stent and method for delivery of same
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US6238872B1 (en) * 1997-04-01 2001-05-29 S.E.T.-Smart Endolumenal Technologies Ltd. Targeted therapy to a biomedical device
US6344055B1 (en) * 1997-05-14 2002-02-05 Novo Rps Ulc Method for production of an expandable stent
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
WO1999023977A1 (en) * 1997-11-07 1999-05-20 Expandable Grafts Partnership Intravascular stent and method for manufacturing an intravascular stent
CA2338093C (en) 1998-07-20 2010-11-30 Shousun C. Szu Vaccines against escherichia coli o157 infection
US6196230B1 (en) * 1998-09-10 2001-03-06 Percardia, Inc. Stent delivery system and method of use
US6293959B1 (en) * 1998-11-16 2001-09-25 Cordis Corporation Balloon catheter and stent delivery system having enhanced stent retention and method
US6270521B1 (en) * 1999-05-21 2001-08-07 Cordis Corporation Stent delivery catheter system for primary stenting
US6241758B1 (en) 1999-05-28 2001-06-05 Advanced Cardiovascular Systems, Inc. Self-expanding stent delivery system and method of use
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6239118B1 (en) * 1999-10-05 2001-05-29 Richard A. Schatz Method for preventing restenosis using a substituted adenine derivative
US6264671B1 (en) * 1999-11-15 2001-07-24 Advanced Cardiovascular Systems, Inc. Stent delivery catheter and method of use
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6306162B1 (en) * 1999-12-15 2001-10-23 Advanced Cardiovascular Systems, Inc. Stent delivery system utilizing novel balloon for obtaining variable post-deployment stent characteristics
US6464986B1 (en) † 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US7300659B2 (en) 2001-01-04 2007-11-27 University Of Saskatchewan Enterohemorrhagic Escherichia coli vaccine
US20020099356A1 (en) * 2001-01-19 2002-07-25 Unger Evan C. Transmembrane transport apparatus and method

Also Published As

Publication number Publication date
US20040142005A1 (en) 2004-07-22
AU2003220511B2 (en) 2006-11-16
ATE355852T1 (de) 2007-03-15
US20030185860A1 (en) 2003-10-02
US6767544B2 (en) 2004-07-27
MXPA04009410A (es) 2005-01-25
WO2003084567A1 (en) 2003-10-16
HK1070575A1 (en) 2005-06-24
US7223399B2 (en) 2007-05-29
US20060127417A1 (en) 2006-06-15
US7494654B2 (en) 2009-02-24
JP2009102440A (ja) 2009-05-14
KR20040105818A (ko) 2004-12-16
US7048927B2 (en) 2006-05-23
JP2013053167A (ja) 2013-03-21
EP1490097B2 (de) 2010-08-18
ES2281636T5 (es) 2010-12-17
US20040223975A1 (en) 2004-11-11
JP2005521735A (ja) 2005-07-21
EP1490097A1 (de) 2004-12-29
DE60312309T3 (de) 2011-02-24
BR0308928A (pt) 2005-01-04
EP1490097B1 (de) 2007-03-07
ES2281636T3 (es) 2007-10-01
AU2003220511C1 (en) 2008-03-06
DE60312309T2 (de) 2007-11-08
AU2003220511A1 (en) 2003-10-20
CA2480505A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EA200971053A1 (ru) Способы лечения кожных язв
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE349523T1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE480232T1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE60021111D1 (de) Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings